Browse the evidence

Older adults disproportionately consume lower-quality plant-based proteins at lunch compared to younger and middle-aged adults, who primarily consume animal-based proteins at the same meal.

At lunch, older adults tend to eat lower-quality plant proteins (like bread) compared to younger people who eat meat or fish. Since animal proteins are more effective at building muscle, try to swap some of your lunch carbohydrates for a high-quality protein source like eggs, yogurt, or lean meat to better support your muscles.

GLP-1 receptor agonist treatment is associated with a statistically significant increase in specific psychiatric adverse events, including nervousness, stress, eating disorders, insomnia, binge eating, fear of eating, and self-induced vomiting, with onset typically occurring within the first 30 days.

If you are taking a GLP-1 medication (like Ozempic, Wegovy, or Trulicity), be aware that psychiatric side effects are a recognized risk, not just a rare anecdote. Symptoms like nervousness, stress, insomnia, and changes in eating behavior (such as bingeing or fear of eating) can start within the first month of treatment. Because these reports are disproportionately high in the database, you should proactively monitor your mental health and mood, especially if you have a history of anxiety or eating disorders, and report any new or worsening symptoms to your prescriber immediately.

Rapid weight loss induced by GLP-1 receptor agonists (e.g., semaglutide) causes significant facial volume depletion and skin laxity, resulting in an aged appearance termed 'Ozempic face'.

If you are taking Ozempic or similar drugs, be aware that rapid weight loss can hollow out your face and make you look older. This is a known side effect. If it happens, consult a plastic surgeon about fillers or skin tightening to restore volume.

Facial volume loss from GLP-1 agonists can be effectively treated with dermal fillers, skin tightening techniques, and surgical interventions.

If your face looks hollow after weight loss, consult a plastic surgeon. Treatments like fillers, lasers, or facelifts can restore volume and tighten skin. Be prepared for the costs and recovery time.

Sex hormone-binding globulin (SHBG) acts as a potential mediator in the causal relationship between higher cardiorespiratory fitness and lower type 2 diabetes risk.

Higher fitness is linked to higher levels of SHBG, which is known to protect against type 2 diabetes. This suggests that improving fitness may work partly by optimizing your hormone binding profiles.

Semaglutide treatment reduces plasma levels of FABP4 and modulates neutrophil phenotype (increasing CD88, reducing CD11b-mediated adhesion), thereby attenuating prothrombotic and atherosclerotic mechanisms.

For patients with Type 2 Diabetes and obesity who are not controlled on oral medications, Semaglutide (0.5-1.0 mg weekly) not only aids weight loss but may also reduce specific cardiovascular risk markers like FABP4 and improve neutrophil behavior, potentially lowering atherosclerosis risk. This benefit is observed after 6 months of treatment.

Baseline metabolite levels (BCAA, tyrosine, betaine, choline) do not predict the magnitude of weight loss achieved after bariatric surgery or lifestyle interventions.

Your baseline blood levels of BCAA, tyrosine, betaine, or choline will not tell you how much weight you will lose after surgery or a diet program. While these markers might predict whether your diabetes remits, they do not predict the magnitude of weight loss.

Psychological distress and emotional baggage from negative life experiences (e.g., childhood trauma, social harassment) act as primary barriers to initiating and sustaining lifestyle changes, often overriding explicit health knowledge.

If you know what to do but can't start, your barrier is likely emotional, not intellectual. Standard advice won't work. You need support that addresses your past trauma and current stress, not just a diet plan. Professional assistance that focuses on emotional resilience is often necessary to break the cycle of 'stuckness'.

Branched-chain amino acid (BCAA) dysregulation directly causes pro-arrhythmic effects, including action potential prolongation and calcium dysregulation, independent of structural cardiac changes.

If you have diabetes or obesity, your risk of dangerous heart rhythms may be linked to how your body processes specific amino acids (leucine, isoleucine, valine) found in protein. While you don't necessarily need to eliminate protein, focusing on dietary patterns that improve metabolic health, such as the Mediterranean diet, may help lower BCAA levels and reduce arrhythmia risk. Consult your doctor about your specific metabolic profile.

Sarcopenic obesity (high BMI with low lean body mass) is associated with increased risk of dose-limiting chemotherapy toxicity and adverse survival outcomes in esophageal cancer patients.

For esophageal cancer patients, body composition (lean muscle mass) is as important as BMI. Doctors should consider lean body mass-based dosing for chemotherapy to reduce toxicity, especially in patients with sarcopenic obesity.

In human visceral and subcutaneous adipose tissue, p38α (Mapk14) mRNA levels inversely correlate with Body Mass Index (BMI) and positively correlate with UCP1 expression.

Humans with higher BMI tend to have lower levels of p38α mRNA in their fat tissue, and this lower level is linked to lower levels of the fat-burning protein UCP1. This suggests that restoring p38α might not be the direct solution, as its role is complex (inhibitory in BAT), but it highlights a biomarker of reduced fat-burning capacity in obesity.

Berberine (BBR) shows multi-target anti-obesity actions in preclinical models (AMPK activation, gut microbiota modulation) but suffers from poor oral bioavailability (<5%) and lacks sufficient clinical validation for obesity.

Berberine is a natural compound with preclinical evidence for weight loss, but it has very low absorption in the body (<5%) and hasn't been proven effective in large clinical trials for obesity. While safe for other uses, it is not yet a recommended treatment for weight loss.

Bariatric surgery does not significantly reduce all-cause mortality compared to conventional medical therapy in severely obese T2DM patients over the long term, although it reduces specific macrovascular events.

While bariatric surgery significantly reduces heart attacks and strokes in severely obese diabetics, this specific analysis did not find a statistically significant reduction in overall death rates compared to medical therapy. The benefits are substantial in terms of preventing major cardiovascular events, even if overall mortality remains similar in this dataset.

Flavonoids inhibit glucose transporters (GLUT2, GLUT5, GLUT7), thereby reducing intestinal glucose and fructose absorption.

Eating flavonoid-rich foods might slightly slow down sugar absorption by affecting transporters in the gut. This is a subtle effect and should not replace a balanced diet, but it may offer some metabolic benefit.

GLP-1 receptor agonists (specifically liraglutide and exendin-4) inhibit cancer progression and proliferation in various malignancies (breast, prostate, pancreatic, ovarian, colon, liver) through mechanisms including apoptosis induction, cell cycle arrest, and inhibition of signaling pathways like PI3K/Akt/mTOR and MAPK.

This paper highlights that while semaglutide (Ozempic/Wegovy) has mixed signals regarding cancer risk in humans, other GLP-1 agonists like liraglutide and exendin-4 have demonstrated anti-cancer effects in laboratory and animal studies. For patients, this underscores the importance of discussing specific drug risks with a doctor, especially those with a history of cancer, as the effect is not uniform across all drugs in this class.

The appetite-suppressing effects of GLP-1 analogs attenuate during the weight maintenance phase, suggesting that the biological drive to lose weight diminishes once a new homeostatic fat mass is reached.

As you reach your target weight, the strong appetite suppression from GLP-1 medications may lessen. This is a normal physiological response as your body adjusts to its new weight. Continued monitoring and potentially lifestyle adjustments may be needed to maintain weight loss.

UPF intake may influence energy intake and metabolic responses through factors like energy density, eating rate, and hyper-palatability, but these mechanisms are not yet fully understood.

Try to be mindful of how quickly you eat and the energy density of your meals. UPFs are often designed to be hyper-palatable and energy-dense, which can lead to overconsumption. Choosing whole, minimally processed foods may help regulate energy intake.

During weight loss maintenance, a low-fat (LF) diet results in significantly lower postprandial energy availability (EA) in the late postprandial period (180-300 minutes) compared to low-glycemic index (LGI) and very low-carbohydrate (VLC) diets, primarily due to suppressed free fatty acid (FFA) and beta-hydroxybutyrate (BHB) levels.

If you are maintaining weight loss, be cautious with very low-fat diets. This study suggests that restricting fat to 20% of calories may reduce your body's ability to use stored energy (fat and ketones) after meals, which could make you more prone to regaining weight. Consider diets with moderate fat (LGI) or higher fat (VLC) to maintain better metabolic fuel availability.

Vegetarian diets do not significantly reduce the risk of gestational diabetes or hypertension in pregnant women compared to omnivorous diets.

If you are pregnant, switching to a vegetarian diet may not specifically reduce your risk of gestational diabetes or high blood pressure compared to a standard diet. Consult your doctor for personalized advice.

For Semaglutide, higher doses are associated with a higher risk of intolerable gastrointestinal adverse reactions.

If you are taking Semaglutide and experiencing intolerable gastrointestinal side effects, discuss with your doctor whether a lower dose (e.g., 0.5mg) might be sufficient to manage your condition with fewer side effects, as higher doses (1mg) are associated with a higher risk of these reactions.

The protective association between plant-based diets and weight loss is weaker or absent in individuals with existing obesity compared to those with normal or overweight status.

If you have obesity, you may find weight loss more challenging with plant-based diets due to metabolic factors like insulin resistance. However, focusing on healthful plant foods remains important for overall health and may still support weight management, even if the effect is less pronounced than in non-obese individuals.

Repeated application of cooling does not affect endurance training adaptations following 4–6 week training interventions.

If you are training for endurance, you can use cold water immersion without worrying about it hurting your long-term aerobic gains. It won't help them either, so use it based on comfort or early recovery needs, not for chronic adaptation.

GLP-1 receptor agonists are associated with a rapid worsening of diabetic retinopathy, particularly in patients with a history of retinopathy and those using insulin, likely due to rapid glycemic improvement.

If you have diabetes and are starting a GLP-1 medication, ensure you have regular eye exams. If you already have eye problems, your doctor may monitor you more closely, as rapid blood sugar improvement can temporarily worsen vision.

Intermittent fasting (IF) is a suboptimal dietary strategy for optimizing muscle protein remodeling and maintaining muscle mass because prolonged fasting periods increase muscle protein breakdown (MPB) and reduce the frequency of muscle protein synthesis (MPS) stimulation, leading to a less favorable net protein balance compared to balanced meal feeding.

If your goal is maximizing muscle size or quality, avoid long fasting windows (e.g., >16 hours) if possible. Spread your protein intake across 3-4 meals every 3-5 hours to keep muscle protein synthesis stimulated. If you practice IF for fat loss, ensure you consume enough total protein (≥1.6 g/kg/day) and consider resistance training to mitigate potential muscle loss.